1. Felson DT, Zhang Y. 1998. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 41:1343-55.
2. Maetzel, A, Makela, M, Hawker, G, Bombardier, C. 1997. Osteoarthritis of the hip and knee and mechanical occupational exposure: a systematic overview of the evidence. J. Rheumatol. 24:599-607; Felson, DT, Lawrence, RC, Dieppte, PA, Hirsch, R, Helmick, CG, Jordan, JM, Kington, RS, Lane, NE, Nevitt, MC, Zhang, Y, Sowers, M, McAlindon, T, Spector, TD, Poole, AR, Yanovski, SZ, Ateshian, G, Sharma, L, Buckwalter, JA, Brandt, KD, Fries, JF. 2000a. Osteoarthritis: New Insights: Part 1: The Disease and Its Risk Factors. Ann Intern Med, 133(8): 635-646; Felson, DT, Lawrence, RC, Hochberg, MC, McAlindon, T, Dieppe, PA, Minor, MA, Blair, SN, Berman, BM, Fries, JF, Weinberger, M, Lorig, KR, Jacobs, JJ, Goldberg, V. 2000b. Osteoarthritis: New Insights. Part 2: Treatment Approaches. Ann Internal Med, 133(9):726-737; Deschner, J, Hofman, CR, Piesco, NP, Argarwal, S. 2003. Signal transduction by mechanical strain in chondrocytes Curr. Opin. Clin. Nutr. Metab. Care. 6: 289-93.
3. Roos EM. 2005. Joint injury causes knee osteoarthritis in young adults. Curr Opin Rheumatol. 17(2):195-200.
4. O’Reilly SC, Jones A, Doherty M. 1998. Quadriceps weakness in knee osteoarthritis: the effect on pain and disability. Ann. Rheum. Dis. 57:588-94; Herzog W, Longino D, Clark A. 2003. The role of muscles in joint adaptation and degeneration. Langenbecks Arch Surg. 388(5):305-15; Felson DT. 2004. Risk factors for osteoarthritis: understanding joint vulnerability. Clin Orthop Relat Res. 427 (Suppl):S16-21.
5. Peat G, McCarney R, Croft P. 2001. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann. Rheum. Dis. 60:91-7.
6. Sprecher, H, Luthria, DL, Mohammed, BS, Baykousheva, SP. 1995. Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids. J. Lipid Res, 36:2471-2477.
7. Dijkgraaf, LC, de Bont, LG, Boering, G, Liem, RS. 1995. The structure, biochemistry, and metabolism of osteoarthritic cartilage: a review of the literature. J Oral Maxillofac Surg. 53(10):1182-92.
8. Plumb, MS, Aspden, RM. 2004. High levels of fat and (n-6) fatty acids in cancellous bone in osteoarthritis. Lipids in Health and Disease, 3:12-14.
9. Lippiello L. 1990. Lipid and cell metabolic changes associated with essential fatty acid enrichment of articular chondrocytes. Proc Soc Exp Biol Med. 195(2):282-7; Hart, DJ, Doyle, DV, Spector, TD. 1995. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol, 22:1118-1123.
10. Aspden, RM, Scheven, BAA, Hutchison, JD. 2001. Osteoarthritis is a systemic disorder involving stromal cell differentiation and lipid metabolism. Lancet. 357:1118-1120.
11. Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM. 2002. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med., 33(8):1097-105.
12. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM. 2002. Epigallocatechin-3-gallate inhibits interleukin-1beta-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB.Arthritis Rheum., 46(8):2079-86.
13. Ham KD, Loeser RF, Lindgren BR, Carlson CS. 2002. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum., 46(7):1956-64.
14. Ishiwa J, Sato T, Mimaki Y, Sashida Y, Yano M, Ito A. 2000. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol., 27(1):20-5.
15. Goetzl EJ, An S, Smith WL. 1995. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 9:1051-1058.
16. The Eicosanoids, Ed. Curtis-Prior P, John Wiley & Sons, New York, NY, 2004
17. Watkins BA, Li Y, Seifert MF. 2001. Nutraceutical fatty acids as biochemical and molecular modulators of skeletal biology. J Am Coll Nutr., 20(5 Suppl):410S-416S.
18. Lippiello, L, Walsh, T, Fienhold, M. 1991. The association of lipid abnormalities with tissue pathology in human osteoarthritic articular cartilage. Metabolism, 40(6):571-6.
19. Felson, DT, Lawrence, RC, Dieppte, PA, Hirsch, R, Helmick, CG, Jordan, JM, Kington, RS, Lane, NE, Nevitt, MC, Zhang, Y, Sowers, M, McAlindon, T, Spector, TD, Poole, AR, Yanovski, SZ, Ateshian, G, Sharma, L, Buckwalter, JA, Brandt, KD, Fries, JF. 2000a. Osteoarthritis: New Insights: Part 1: The Disease and Its Risk Factors. Ann Intern Med, 133(8): 635-646.
20. Bonizzi, G, Piette, J, Schoonbroodt, S, Greimers, R, Harvard, L, Merville, MP, Bours, V. 1999. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity.  Mol. Cell. Biol. 19:1950-60.
21. Hardy, MM, Seibert, K, Manning, PT, Currie, MG, Woerner, BM, Edwards, D, Koki, A, Tripp, CS. 2002. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 46: 1789-803.
22. Steiner, DR, Gonzalez, NC, Wood, JG. 2001. Leukotriene B4 promotes reactive oxidant generation and leukocyte adherence during acute hypoxia. J Appl Physiol, 91: 1160–1167.
23. Martel-Pelletier J, Mineau F, Fahmi H, Laufer S, Reboul P, Boileau C, Lavigne M, Pelletier JP. 2004. Regulation of the expression of 5-lipoxygenase-activating protein-5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids. Arthrits Rheum. 50(12):3925-33; Marcouiller P, Pelletier JP, Guevremont M, Martel-Pelletier J, Ranger P, Laufer S, Reboul P. 2005. Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membrane: regulating factors for interleukin 1beta synthesis. J. Rheumatol. 32(4):704-12.
24. Dannhardt, G, Kiefer, W. 2001. Cyclooxygenase inhibitors--current status and future prospects, Eur. J. Med. Chem, 36: 109-26.
25. Martel-Pelletier, J, Lajeunesse, D, Reboul, P, Pelletier, JP. 2003. Therapeutic Role of Dual Inhibitors of 5-LOX and COX, Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs. Ann. Rhem. Dis, 62:501-09.
26. Hudson, N, Balsitis, M, Everitt, S, Hawkey, CJ. 1993. Enhanced Gastric Mucosal Leukotriene B4 Synthesis in Patients Taking Non-steroidal Anti-Inflammatory Drugs. Gut, 34:742-7.
27. Laufer S. 2001. Discovery and development of ML3000. Inflammopharmacology. 9(1-2):101-112.   
28. Bunting, S, Moncada, S, Vane, JR. 1983. The prostacyclin—thromboxane A2 balance: pathophysiological and theraputic implications. Br. Med. Bull. 39:271-6.
29. Solomon DH. 2005. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum. 52(7):1968-78; Bing, RJ, Lomnicka, M. 2002. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?   J. Am Coll Cardiol. 39:421.
30. Sowers MF. 2001. Epidemiology of risk factors of osteoarthritis: systemic factors. Cur Opinion Rheum, 13(5):447-451; Yudoh K, van Trieu N, Nakamura H, Hongo-Masuko K, Kato T, Nishioka K. 2003. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and down-regulation of chondrocyte function. Arthritis Res. Ther. 7:R380-R391.
31. Basu, S, Whiteman, M, Mattey, DL, Halliwell, B. 2001. Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases.  Ann Rheum Dis. 60:627-31.
32. Tiku, ML, Gupta, S, Deshmukh, DR. 1999. Aggrecan degradation in chondrocytes is mediated by reactive oxygen species and protected by antioxidants. Free Rad Res, 30:395-405.
33. Meydani, M. 2001. Nutrition interventions in aging and age-associated disease. Ann N Y Acad Sci, 928:226-35.
34. Miquel, J. 2001. Nutrition and Ageing. Public Health Nutr, 4(6A):1385-8.
35. McAlindon, TE, Jacques, P, Zhang, Y, et al. 1996a. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum, 39(4):648-656.
36. Henrotin YE, Bruckner P, Pujol JP. 2003. The role of reactive oxygen species in homeostatis and degradation of cartilage.Osteoarthritis and Cartilage 2003;11:747-55; Nelson, KK Melendez, JA. 2004. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med. 37(6):768-84.
37. Blankenhorn, G. 1986. Clinical efficacy of spondyvit (vitamin E) in activated arthroses. A multicenter, placebo-controlled, double-blind study. Z Orthop. 124:340-343; Scherak, O, Kolarz, G, Schodl, C, Blankenhorn, G. 1990. High dosage vitamin E therapy in patients with activated arthrosis. Z Rheumatol. 49:369-373; Kraus, VB, Huebner, JL, Stabler, T, et al. 2004. Ascorbic acid increases the severity of spontaneous knee osteoarthritis in a guinea pig model. Arthritis Rheum. 50(6):1822-31.
38. Arts, IC, Hollman, PCH. 2005. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr. 81(1):317S-25S.
39. Patton, JS, Shepard, HM, Wilking, H, Lewis, G, Aggarwal, BB, Eessalu, TE, Gavin, LA, Grunfeld, C. 1986. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA. 83(21):8313-7.
40. Cao, GH, Alessio, HM, Cutler, RG. 1993. Oxygen-radical absorbency capacity assay for antioxidants. Free Radic Biol Med. 14:303-311.